Physiologically based pharmacokinetic modeling of persistent organic pollutants for lifetime exposure assessment: A new tool in breast cancer epidemiologic studies

Environmental Health Perspectives

Volumn 116, Issue 7, 2008, Pages 886-892

  Verner, Marc André ^a   Charbonneau, Michel ^b   López Carrillo, Lizbeth ^c   Haddad, Sami ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Breast cancer; Epidemiology; Exposure assessment; Persistent organic pollutants; Physiologically based pharmacokinetic modeling

Indexed keywords

HEXACHLOROBENZENE; ORGANIC COMPOUND; POLYCHLORINATED BIPHENYL; POLYCHLORINATED BIPHENYL DERIVATIVE;

AGE; ARTICLE; BLOOD FLOW; BLOOD LEVEL; BODY COMPOSITION; BODY HEIGHT; BODY WEIGHT; BREAST CANCER; BREAST CARCINOGENESIS; BREAST FEEDING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; HYPOTHESIS; LACTATION; LIFESPAN; MATHEMATICAL MODEL; MEDICAL RESEARCH; ORGAN SIZE; PHYSICAL DEVELOPMENT; PREGNANCY; PRIORITY JOURNAL; SIMULATION; TISSUE LEVEL; TOXICOKINETICS; WEIGHT CHANGE;

BODY HEIGHT; BODY WEIGHT; BREAST FEEDING; BREAST NEOPLASMS; COMPUTER SIMULATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; MATERNAL EXPOSURE; MODELS, BIOLOGICAL; ORGANIC CHEMICALS; RISK ASSESSMENT; TIME FACTORS;

EID: 46749139544     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.10917     Document Type: Article

References (58)

1. Anderson MW, Eling TE, Lutz RJ, Dedrick RL, Matthews HB. 1977. The construction of a pharmacokinetic model for the disposition of polychlorinated biphenyls in the rat. Clin Pharmacol Ther 22:765-773.
2. Andersson PL, Blom A, Johannisson A, Pesonen M, Tysklind M, Berg AH, et al. 1999. Assessment of PCBs and hydroxylated PCBs as potential xenoestrogens: in vitro studies based on MCF-7 cell proliferation and induction of vitellogenin in primary culture of rainbow trout hepatocytes. Arch Environ Contam Toxicol 37:145-150.
3. Aronson KJ, Miller AB, Woolcott CG, Sterns EE, McCready DR, Lickley LA, et al. 2000. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol Biomarkers Prev 9:55-63.
4. ATSDR. 2000. Toxicological Profile for Polychlorinated Biphenyls (PCBs). Atlanta, GA:Agency for Toxic Substances and Diseases Registry.
5. ATSDR. 2002. Toxicological Profile for Hexachlorobenzene. Atlanta, GA:Agency for Toxic Substances and Diseases Registry.
6. Barr DB, Weihe P, Davis MID, Needham LL, Grandjean P. 2006. Serum polychlorinated biphenyl and organochlorine insecticide concentrations in a Faroese birth cohort. Chemosphere 62:1167-1182.
7. Belfiore CJ, Yang RS, Chubb LS, Lohitnavy M, Lohitnavy OS, Andersen ME. 2007. Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling. Toxicology 234:59-72.
8. Brody JG, Rudel RA. 2003. Environmental pollutants and breast cancer. Environ Health Perspect 111:1007-1019.
9. Calle EE, Frumkin H, Henley SJ, Savitz DA, Thun MJ. 2002. Organochlorines and breast cancer risk. CA Cancer J Clin 52:301-309.
10. Carrier G. 1991. Réponse de l'organisme humain aux BPC, dioxines et furannes at analyse des risques toxiques. Québec:Le Passeur.
11. Charlier C, Albert A, Herman P, Hamoir E, Gaspard U, Meurisse M, et al. 2003. Breast cancer and serum organochlorine residues. Occup Environ Med 60:348-351.
12. Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79:381-393.
13. Cohn BA, Wolff MS, Cirillo PM, Sholtz RI. 2007. DDT and breast cancer in young women: now data on the significance of age at exposure. Environ Health Perspect 115:1406-1414.
14. Davis JW II, Lauer FT, Burdick AD, Hudson LG, Burchiel SW. 2001. Prevention of apoptosis by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-10A cell line: correlation with increased transforming growth factor alpha production. Cancer Res 61:3314-3320.
15. Demers A, Ayotte P, Brisson J, Dodin S, Robert J, Dewailly E. 2002. Plasma concentrations of polychlorinated biphenyls and the risk of breast cancer: a congener-specific analysis. Am J Epidermol 155:629-635.
16. Dewailly É, Ayotte P, Laliberte C, Weber JP, Gingras S, Nantel AJ. 1996. Polychlorinated biphenyl (PCB) and dichlorodiphenyl dichloroethylene (DDE) concentrations in the breast milk of women in Quebec. Am J Public Health 86:1241-1246.
17. Du K, Chu S, Xu X. 2000. Stimulation of MCF-7 cell proliferation by low concentrations of Chinese domestic polychlorinated biphenyls. J Toxicol Environ Health A 61:201-207.
18. Emond C, Charbonneau M, Krishnan K. 2005. Physiologically based modeling of the accumulation in plasma and tissue lipids of a mixture of PCB congeners in female Sprague-Dawley rats. J Toxicol Environ Health A 68:1393-1412.
19. Gentry PR, Covington TR, Andersen ME, Clewell HJ III. 2002. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 36:51-68.
20. Gentry PR, Covington TR, Clewell HJ III. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol 38:1-16.
21. Haddad S, Poulin P, Krishnan K. 2000. Relative lipid content as the sole mechanistic determinant of the adipose tissue:blood partition coefficients of highly lipophilic organic chemicals. Chemosphere 40:839-843.
22. Haddad S, Restieri C, Krishnan K. 2001. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J Toxicol Environ Health A 64:453-464.
23. Haddad S, Tardif GC, Tardif R. 2006. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J Toxicol Environ Health A 69:2095-2136.
24. Hoel DG, Dinse GE. 1990. Using mortality data to estimate radiation effects on breast cancer incidence. Environ Health Perspect 87:123-129.
25. Hoyer AP, Jorgensen T, Brock JW, Grandjean P. 2000. Organochlorine exposure and breast cancer survival. J Clin Epidemiol 53:323-330.
26. Kreuzer PE, Csanady GA, Baur C, Kessler W, Papke O, Greim H, et al. 1997. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human life-time body burden by TCDD with special emphasis on its uptake by nutrition. Arch Toxicol 71:383-400.
27. Krishnan K, Andersen ME. 2001. Physiologically based pharmacokinetic modeling in toxicology. In: Principles and Methods of Toxicology. 4th ed. (Hayes AW, ed). Philadelphia:Taylor and Francis, 193-241.
28. Laden F, Collman G, Iwamoto K, Alberg AJ, Berkowitz GS, Freudenheim JL, et al. 2001. 1,1-Dichloro-2,2-bis(p- chlorophenyl)ethylene and polychlorinated biphenyls and breast cancer: combined analysis of five U.S. studies. J Natl Cancer Inst 93:768-776.
29. Lee SK, Ou YC, Andersen ME, Yang RS. 2007. A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice. Arch Toxicol 81:101-111.
30. Lee SK, Ou YC, Yang RS. 2002. Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups. Toxicol Sci 65:26-34.
31. Lopez-Cervantes M, Torres-Sanchez L, Tobias A, Lopez-Carrillo L 2004. Dichlorodiphenyldichloroethane burden and breast cancer risk: a meta-analysis of the epidemiologic evidence. Environ Health Perspect 112:207-214.
32. Lu Y, Lohitnavy M, Reddy MB, Lohitnavy O, Ashley A, Yang RS. 2006. An updated physiologically based pharmacokinetic model for hexachlorobenzene: incorporation of pathophysiological states following partial hepatectomy and hexachlorobenzene treatment. Toxicol Sci 91:29-41.
33. Lutz RJ, Dedrick RL, Matthews HB, Eling TE, Anderson MW. 1977. A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat. Drug Metabol Dispos 5:386-396.
34. Lutz RJ, Dedrick RL, Tuey D, Sipes IG, Anderson MW, Matthews HB. 1984. Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. Drug Metab Dispos 12:527-535.
35. Machala M, Blaha L, Lehmler HJ, Pliskova M, Majkova Z, Kapplova P, et al. 2004. Toxicity of hydroxylated and quinoid PCB metabolites: inhibition of gap junctional intercellular communication and activation of aryl hydrocarbon and estrogen receptors in hepatic and mammary cells. Chem Res Toxicol 17:340-347.
36. Maruyama W, Yoshida K, Tanaka T, Nakanishi J. 2003. Simulation of dioxin accumulation in human tissues and analysis of reproductive risk. Chemosphere 53:301-313.
37. Meerts IA, Hoving S, van den Berg JH, Weijers BM, Swarts HJ, van der Beek EM, et al. 2004. Effects of in utero exposure to 4-hydroxy-2,3,3′,4′,5-pentachlorobiphenyl (4-OH-CB107) on developmental landmarks, steroid hormone levels, and female estrous cyclicity in rats. Toxicol Sci 82:259-267.
38. Neville MC, Allen JC, Archer PC, Casey CE, Seacat J, Keller RP, et al. 1991. Studies in human lactation: milk volume and nutrient composition during weaning and lactogenesis. Am J Ciin Nutr 54:81-92.
39. Parham FM, Portier CJ. 1998. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. Toxicol Appl Pharmacol 151:110-116.
40. Poulin P, Krishnan K. 1996. A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Toxicol Appl Pharmacol 136:126-130.
41. Price K, Haddad S, Krishnan K. 2003. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J Toxicol Environ Health A 66:417-433.
42. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, et al. 2003. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 33:469-503.
43. Romieu I, Hernandez-Avila M, Lazcano-Ponce E, Weber JP, Dewailly É. 2000. Breast cancer, lactation history, and serum organochlorines. Am J Epidemiol 152:363-370.
44. Safe SH. 1994. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. Crit Rev Toxicol 24:87-149.
45. Solomon GM, Weiss PM. 2002. Chemical contaminants in breast milk: time trends and regional variability. Environ Health Perspect 110:A339-A347.
46. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. 1995. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect 103(suppl 7):113-122.
47. To-Figueras J, Barrot C, Sala M, Otero R, Silva M, Ozalla MD, et al. 2000. Excretion of hexachlorobenzene and metabolites in feces in a highly exposed human population. Environ Health Perspect 108:595-598.
48. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. 1994. Incidence of female breast cancer among atomic bomb survivors, 1950-1905. Radiat Res 138:209-223.
49. Tuey DB, Matthews HB. 1977. Pharmacokinetics of 3,3′,5,5′-tetrachlorobiphenyl in the male rat. Drug Metab Dispos 5:444-450.
50. Tuey DB, Matthews HB. 1980a. Distribution and excretion of 22′,4,4′,5,5′-hexabromobiphenyl in rats and man: pharmacokinetic model predictions. Toxicol Appl Pharmacol 53:420-431.
51. Tuey DB, Matthews HB. 1980b. Use of a physiological compartmental model for the rat to describe the pharmacokinetics of several chlorinated biphenyls in the mouse. Drug Metab Dispos 8:397-403.
52. van der Molen GW, Kooijman SA, Slob W. 1996. A generic toxicokinetic model for persistent lipophilic compounds in humans: an application to TCDD. Fundam Appl Toxicol 31:83-94.
53. Wolff MS, Anderson HA, Britton JA, Rothman N. 2007. Pharmacokinetic variability and modern epidemiology - the example of dichlorodiphenyltrichloroethane, body mass index, and birth cohort, Cancer Epidemiol Biomarkers Prev 16:1925-1930.
54. Wolff MS, Britton JA, Teitelbaum SL, Eng S, Deych E, Ireland K, et al. 2005. Improving organochlorine biomarker models for cancer research. Cancer Epidemiol Biamarkers Prev 14:2224-2236.
55. Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. 1993. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 85:648-652.
56. Yesair DW, Feder PI, Chin AE, Naber SJ, Kuiper-Goodman T, Scott CS, et al. 1986. Development, evaluation and use of a pharmacokinetic model for hexachlorobenzone. [ARC Sci Pub 297-318.
57. You L, Gazi E, Archibeque-Engle S, Casanova M, Conolly RB, Heck HA. 1999. Transplacental and lactational transfer of p,p'-DDE in Sprague-Dawley rats. Toxicol Appl Pharmacol 157:134-144.
58. You SH, Gauger KJ, Bansal R, Zoeller RT. 2006. 4-Hydroxy-PCB106 acts as a direct thyroid hormone receptor agonist in rat GH3 cells. Mol Cell Endocrinol 257-258:26-34.